Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?

Annals of Internal Medicine

Volumn 132, Issue 2, 2000, Pages 134-143

  Feldman, Mark ^a   McMahon, Alexander T ^b  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b Oncology Therapeutics Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FLOSULIDE; NAPROXEN; NIMESULIDE; ROFECOXIB;

ARTHRITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; HUMAN; META ANALYSIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVIEW;

EID: 0033971402     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-2-200001180-00008     Document Type: Review

References (73)

1. Hawkey CJ. COX-2 inhibitors. Lancet 1999;53:307-14.
2. Celecoxib for arthritis. Med Lett Drugs Ther 1999;1:11-2.
3. Rofecoxib for osteoarthritis and pain. Med Lett Drugs Ther. 1999;41:59-61.
4. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104:413-21.
5. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999;26(Suppl 56):18-24.
6. Harris RC, Wang JL, Cheng HF, Zhang MZ, McKanna JA. Prostaglandins in macula densa function. Kidney Int Suppl. 1998;54:549-52.
7. Cheng HF, Wang JL, Zhang MZ, Miyazaki Y, Ichikawa I, McKanna JA, et al. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest. 1999;103:953-61.
8. Kaufmann WE, Worley PF, Pegg J, Bremer M, lsakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci U S A. 1996;93:2317-21.
9. Tocco G, Freire-Moar J, Schreiber SS, Sakhi SH, Aisen PS, Pasinetti GM. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Exp Neurol. 1997;144:339-49.
10. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell. 1997;91:197-208.
11. Lim H, Gupta RA, Ma WG, Paria BC, Moller DE, Morrow JD, et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARA. Genes Dev. 1999;13:1561-74.
12. Celebrex product literature. Chicago: GD. Searle & Co; 1998
13. Rofecoxib product literature. West Point, PA: Merck & Co, Inc; 1999.
14. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther. 1999;66:76-84.
15. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107: 1183-8.
16. Beyond pair relief. Drug firms try to put new arthritis medicine to use battling cancer. Makers of Celebrex and Vioxx are racing to test them against tumors of colon. The Wall Street Journal. 7 Sep 1999.
17. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121:241-6.
18. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulincac in familial adenomatous polyposis. N Engl J Med. 1993;328:1313-6.
19. Cryer B, Gottesdiener K, Gertz B, Hsieh P, Dallob A, Feldman M. Effects of a novel cyclooxygenase(COX)-2 inhibitor on gastric mucosal prostaglandin (PG) synthesis in healthy humans [Abstract]. Am J Gastroenterol. 1996;91: 1907.
20. Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW, et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res. 1996;45:68-74.
21. Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol. 1997;48: 623-31.
22. Santini G, Sciulli MG, Panara MR, Padovano R, di Giamberardino M, Rotondo MT, et al. Effects of flurbiprofen and flurbinitroxybutylester on prostaglandin endoperoxide synthases. Eur J Pharmacol. 1996;316:65-72.
23. Panara MR, Greco A, Santini G, Sciulli MG, Rotondo MT, Padovano R. et al. Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamice (NS-398) and 5-methanesulphonamido-6-(2,4-diffuorotnio-phenyl)-1-inda none (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. Br J Pharmacol. 1995;16:2429-34.
24. Panara MR, Padovano R, Sciulli MG, Santini G, Renda G, Rotondo MT, et al. Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings. Clin Pharmacol Ther. 1998;63:672-81.
25. Glaser K, Sung ML, O'Neill K, Belfast M, Hartman D, Carlson R, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol. 1995;281:107-11.
26. 2 formation in tissue from human colonic mucosa and chronic bursitis [Abstract]. Gastroenterology. 1998;114:A139.
27. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain Proc Natl Acad Sci U S A. 1994:91:12013-7
28. Wallace JL, Bak A, McKnight W, Asfaha S, Sharkey KA, MacNaughton WK. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology. 1998;115 101-9.
29. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflamrratory properties. Nat Med. 1999;5:698-701.
30. Schwartz JI, Chan CC, Mukhopadhyay S, McBride KJ, Jones TM, Adcock S, et al. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. C in Pharmacol Ther. 1999;65:653-60.
31. Zimmerman KC, Sarbia M, Schror K, Weber AA. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol. 1998;54:536-40.
32. Iseki S. Immunocytochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach. Histochem J. 1995;27:323-8.
33. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J, et al. Characterization of prostaglandm G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts Gastroenterology. 1996,111:445-54.
34. Robert A, Nezamis JE, Lancaster C, Davis JP, Field SO, Hanchar AJ. Mild irritants prevent gastric necrosis through "adaptive cytoprotection" mediated by prostaglandins. Am J Physiol. 1983;245:G113-G121.
35. Gretzer B, Ehrlich K, Maricic N, Lambrecht N, Respondek M, Peskar BM. Selective cyclo-oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach.Br J Pharmacol 1998;123: 927-35.
36. Schmassmann A. Mechanisms of ulcer healing and effects of nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104(3A) 435-51S.
37. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specify antagonist delays healing in mice. Gastroenterology. 1997; 112:387-97.
38. Takahashi S, Shigeta J, Inoue H, Tanabe T, Okabe S. Localization of cyclooxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats. Am J Physiol. 1998;275(5 Part 1):G1137-G1145.
39. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of non-steroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888-99.
40. García Rodriguez LA. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104: 30S-34S.
41. Schattenkirchner M. An updated safety profile of etodolac in several thousand patients. Eur J Rheumatol Inflamm. 1990;10:56-65.
42. Friedel HA, Langtry HD, Buckley MM. Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases. Drugs. 1993;45: 131-56.
43. Colberg K, Hettich M, Sigmund R, Degner FL. The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Curr Med Res Opin. 1996;13:363-77.
44. Bosch HC, Sigmund R, Hettich M. Efficacy and tolerability of intramuscular and oral meloxicam in patients with acute lumbago: a comparison with intramuscular and oral piroxicam. Curr Med Res Opin. 1997:14:29-38.
45. Carrabba M, Paresce E, Angelini M, Galanti A, Marini MG, Cigarini P. A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthntis: a single-blind, randomized, multicentre study. Curr Med Res Opin. 1995;13:343-55.
46. Lemmel EM, Bolten W, Burgos-Vargas R, Platt P, Nissila M, Sahlberg D, et al. Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J Rheumatol. 1997;24:282-90.
47. Lund B, Distel M, Bluhmki E. A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. Scand J Rheumatol. 1998;27:32-7.
48. Goei The HS, Lund B, Distel MR, Bluhmki E. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 1997;5:283-8.
49. Linden B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with Osteoarthritis of the hip. Br J Rheumatol. 1996,35(Suppl 1):35-8.
50. Hosie J, Distel M, Bluhmki E. Meloxicam in osleoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br J Rheumatol. 1996; 35(Suppl 1):39-43.
51. Wojtulewski JA, Schattenkirchner M, Barcelo P, Le Loet X, Bevis PJ, Bluhmki E, et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 75 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis Br J Rheumatol. 1996;35(Suppl 1):22-8.
52. Dreiser RL, Riebenfeld D. A double-blind study of the efficacy of nimesulide in the treatment of ankle sprain in comparison with placebo Drugs 1993; 46(Suppl 1):183-6.
53. Lecomte J, Buyse H, Taymans J, Monti T. Treatment of tendinitis and bursitis: a comparison of nimesulide and naproxen sodium in a double-blind parallel trial. Eur J Rheumatol Inflanm. 1994;14:29-32.
54. Dreiser RL, Riebenfeld D. Nimesulide in the treatment of osteoarthritis. Double-blind studies in comparison with piroxicam, ketoprofen and placebo. Drugs. 1993;46(Suppl 1):191-5.
55. Porto A, Almeida H, Cunha MJ, Macciocchi A. Double-blind study evaluating by endoscooy the tolerability of nimesulide and diclofenac on the gastric mucosa in osteoarthntic patients. Eur J Rheumatol Inflamm. 1994;14: 33-8.
56. Bourgeois P, Dreiser RL, Lequesne MG, Macciocchi A, Monti T. Multicentre double-blind study to define the most favourable dose of nirresulide in terms of efficacy/safety ratio in the treatment of osteoarthritis. Eur J Rheumatol Inflamm. 1994;14:39-50.
57. Lucker PW, Pawlowski C, Friedrich I, Faiella F, Magni E. Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodolac in patients suffering from osteoarthritis of the knee. Eur J Rheumatol Infamm. 1994;14:29-38.
58. Bjarnason I, Macpherson A, Rotman H, Schupp J, Hayllar J. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen. Scand J Gastroenterol. 1997:32:126-30.
59. Simon LS, Lanza FL, Lipsky PE. Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635. a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controllec trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41:1591-602.
60. Hubbard R, Gels S, Woods E, Yu S, Zhao W. Efficacy, tolerability, and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis [Abstract]. Arthritis Rheum. 1998;41(9 Suppl):S196.
61. Geis S, Stead H, Morant S, Naudin R, Hubbard R. Eficacy and safety of celecoxib, a specific COX-2 nhibitor, in patients with rheumatoid arthritis [Abstract]. Arthritis Rheum. 1998;41(9 Suppl):S316.
62. Geis S, Hubbard R, Callison D, Yu S, Zhao W. Safety and efficacy of celecoxib, a specific COX-2 nhibitor, in patients with rheumatoid arthritis [Abstract]. Arthritis Rheum. 1998;41(9 Suppl):S364.
63. Cannon G, Caldwell J, Holt P, McLean B, Zeng Q, Ehrich E, et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial [Abstract]. Arthritis Rheum. 1998,41(9 Suppl):S196.
64. Saag K, Fisher C, McKay J, Ehrich E, Zhao PL, Bolognese J, et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip csteoarthntis (OA) in a 6-week controlled clinical trial [Abstract],Arthritis Rheum.198:41(9 Suppl):S196.
65. Laine L, Hawkey C, Harper S, Mortensen E, Beaulieu A, Quan H, et al. Effect of the COX-2 specific inhibitor rofeccxib on ulcer formation: a double-blind comparison with ibuprofen and placebo [Abstract] Gastroenterology 1999;116:A229.
66. Goldstein JL, Agrawal NM, Silverstein F, Kaiser J, Burr AM, Verburg KM, et al. Celecoxib is associated with a significantly lower incidence of clinically significant upper gastrointestinal (UGI) events in osteoarthritis (OA) and rheumatoid arthritis (RA) patients as compared to NSAIDs [Abstract]. Gastroenterology. 1999;116: A174.
67. 2) synthesis in healthy humans [Abstract]. Gastroenterology. 1999;116:A141.
68. Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than eitner asprin or ibuprofen. Aliment Pharmacol Ther. 1999;13:761-7.
69. Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, et al. Characterization of rofecoxib as a cyclooxgenase-2 isoform inhibitor and demonstration of analgesia in tne dental pain model. Clin Pharmacol Ther. 1999;65:336-47.
70. Brown J, Morrison BW, Christensen S, Dunkley V, Sandrer M, Turpin M, et al. MK-0966 50 mg versus ibuprofen 400 mg in post surgical dental pain [Abstract]. Clin Pharmacol Ther. 1999,65:118.
71. Fricke J, Morrison BW, Fite S, Sandler M, Yuan W, Howard C, et al. MK-966 versus naproxen sodium 550 mg in post-surgical dental pain [Ab-stract]. Clin Pharmacol Ther. 1999;65:119.
72. Brown J, Morrison BW, Bitner M, Woolsey C, Sandier M, Dunkley V. et al. The COX-2 specific inhibitor, MK-0966, is effective in the treatment of primary dysmenorrhea [Abstract]. Clin Pharmacol Ther. 1999;65:118:
73. Langman M, Jensen DM, Watson DJ, Harper SE, Zhao PL, Guan H, et al. Adverse upper gastrointestinal effects of rofeccxib compared with NSAIDs. JAMA. 1999;282:1929-33.